New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...
Healthcare AI is scaling faster than clinical safety. Without clinicians in the loop, companies face growing liability, ...
Mental health care faces a paradox: demand has surged to record levels, yet the infrastructure supporting clinicians remains ...
12h
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 TrialConstructive Type C Meeting Provides Potential Pathway to Accelerated ...
Q1 2026 Earnings Call Transcript January 8, 2026 Simulations Plus, Inc. misses on earnings expectations. Reported EPS is ...
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
Background Medical specialists are integral to the medical workforce and play a pivotal role in referral systems. However, in ...
You’re reading your child’s IEP, evaluation report, or behavior plan and suddenly you’re stuck on a phrase that feels ...
Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented Dosing of the final cohort in the first in human study has been initiated Studies in ulcerative colitis and ...
Introduction Many neonatal deaths are avoidable using existing low-cost evidence-based interventions. This study evaluated ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback